Considering the EmpowerVax-L1 clinical research study?

If you have been recently diagnosed with non-small-cell lung cancer (NSCLC), you are not alone in your medical journey. NSCLC is the most common type of lung cancer in the US, accounting for 84% of all lung cancer diagnoses.

Currently, we are developing potential treatments for NSCLC. EmpowerVax-L1 is a clinical research study that aims to study a combination of two immunotherapy treatments to treat NSCLC with PD-L1 expression. EmpowerVax-L1 aims to see how effective the combination with an investigational cancer vaccine is in comparison with one of the study treatments by itself. The study will also look at how to better understand the study treatment and advanced NSCLC.

What are the study treatments?

Investigational treatment: The investigational treatment is a cancer vaccine that works by teaching the immune system to recognize cancer cells and remove them from the body.

Approved treatment: The approved treatment is a monoclonal antibody designed to block the action of another protein that may also play a role in preventing immune cells from destroying cancer cells. Blocking this protein may help immune cells destroy cancer cells. Antibodies are proteins that are naturally found in your blood that fight infections.

If you pass the screening phase and join the study, you will be randomly (by chance) assigned to 1 of 2 treatment arms below. You will have an equal (50%) chance of being assigned to either group.

The two treatment arms are:

Treatment Arm A:

This treatment arm will receive only the approved treatment once per cycle (every 3 weeks).

Treatment Arm B:

This treatment arm will receive a combination of the investigational treatment and the approved treatment at various timepoints throughout each 3-week cycle.

What can I expect if I join this study?

Study participation is 100% voluntary (your choice). You will receive information on what to expect, as well as your role and responsibilities if you join the EmpowerVax-L1 study. You may leave the study at any time without it affecting your regular health care.

If you join the study, there are certain things you will be expected to do. This includes attending study visits and undergoing certain assessments and procedures including chest X-rays, imaging scans, biopsies, and blood draws. Your participation may last up to 3 years.

Qualified participants may be reimbursed for travel to and from study visits, and medical care related to their participation, including the study treatment, may be provided at no cost. The study team will discuss all of this with you.

How can I take part?

If you wish to take part in EmpowerVax-L1, you can fill in a short
pre-screener questionnaire to see if you may be eligible.

Am I eligible? >>

What else should I know?

As with all medicines, there are possible risks when taking the study treatments. If you qualify and choose to join this study, you will be provided with an Informed Consent Form that explains any possible risks and side effects. It is also possible that the study treatments may affect you in unknown ways. Your health and safety are our top priorities and will be closely monitored throughout your participation.

There is no guarantee that you will receive a medical benefit from participating in this study. Your condition may get better, stay the same, or may even get worse. You are free to withdraw from the study for any reason and at any time.

Find a study site near you

To find out more about EmpowerVax-L1, and whether it may be right for you,
please contact your closest study site – they will be more than happy to help.

Find your nearest study site >>